Wedbush hikes target on Receptos

|By:, SA News Editor

Market chatter suggests Wedbush is out with a price target hike to $44 (from $26) for Receptos (RCPT -0.8%).

Rationale: Optimism for RPC1063's potential in IBD,

BMO was out with a similarly bullish call ($41 target) earlier this month, highlighting development of RPC1063 in Relapsing Multiple Sclerosis.